E0504
Ecarin from Echis carinatus venom
prothrombin activator
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Prodotti consigliati
Origine biologica
Echis carinatus venom
Livello qualitativo
Confezionamento
vial of 45-55 units
Temperatura di conservazione
−20°C
Applicazioni
Ecarin from Echis carinatus venom is the primary reagent in the ecarin clotting time (ECT) test, which is used to monitor anticoagulation and thrombin inhibition. It has been used in studies to test the effectiveness of medications for the treatment of venous and arterial thromboembolism.
Ecarin activity is the principal behind the Ecarin Clotting Time (ECT) assay, which is used to assess antithrombotic effect and thrombin inhibition.
Azioni biochim/fisiol
Prothrombin activator
Definizione di unità
One unit will activate prothrombin to produce one unit of amidolytic activity at pH 8.4 at 37 °C. One amidolytic unit will hydrolyze 1.0 μmole of N-p-tosyl-Gly-Pro-Arg-p-nitroanilide per min at pH 8.4 at 37 °C.
Avvertenze
Danger
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Resp. Sens. 1 - Skin Sens. 1
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Dispositivi di protezione individuale
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Elise S Eerenberg et al.
Circulation, 124(14), 1573-1579 (2011-09-09)
Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of
Wei Zhou et al.
Stroke, 42(12), 3594-3599 (2011-10-15)
Dabigatran-etexilate (DE) recently has been approved for stroke prevention in atrial fibrillation. However, lack of effective antagonists represents a major concern in the event of intracerebral hemorrhage (ICH). The aims of the present study were to establish a murine model
Lambro A Johnson et al.
Analytical biochemistry, 608, 113907-113907 (2020-08-20)
Snake venom prothrombin activators such as Ecarin are readily assayed by continuous spectrophotometric monitoring of p-nitroaniline production in a one step assay containing prothrombin and a p-nitroanilide peptide substrate for thrombin. The coupled reactions result in accelerating p-nitroaniline (pNA) production
Kevin Dietrich et al.
Thrombosis research, 135(4), 630-635 (2015-02-27)
Age-related changes in the hemostatic system result in variation in response to anticoagulants and coagulation assays over childhood. This study used in vitro methods to determine i) optimum coagulation assays for dabigatran in children and ii) anticoagulant effect of dabigatran
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.